Our Partners

RSS Investor Relations and News

  • MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders December 14, 2018
    CEDAR KNOLLS, N.J., Dec. 14, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, issued the following letter to shareholders from MYOS [...]
    MYOS RENS Technology Announces Results of Its 2018 Annual Meeting of Stockholders December 13, 2018
    ERIC ZALTAS JOINS BOARD OF DIRECTORS CEDAR KNOLLS, N.J., Dec. 13, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced the [...]
    Learn More ›
  • 2018 Annual Meeting of Stockholders

    45 Horsehill Road, Suite 106, Cedar Knolls, New Jersey 07927

    Q3 2018 Financial Results Conference Call

    A replay is available until February 9, 2019 and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, using the Conference ID# 13684940.


    Webcast

Stock Snapshot

MYOS Symbol
NASDAQ Market
Market Cap
Price
Change
Volume